{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 3160, "factors": [{"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM366179": {"Clinical Information": "not responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}, {"GSM36619": {"Clinical Information": "responsive to imatinib therapy"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of...", "pubmed_id": 19837975, "geo_gse_id": "E-GEOD-14671", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 1, "sample_count": 59, "tags": ["chronic myeloid leukemia", "leukemia", "myeloid leukemia"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-of-cd34-positive-mononucle", "geo_id_plat": "E-GEOD-14671_A-AFFY-44", "name": "Transcription profiling of CD34 positive mononuclear cells from drug naive, chronic myeloid leukemia (CML) patients to determine an expression signature predictive of  a major cytogenic response in CML patients treated with Imatinib.", "created": "Sep.11, 2014", "summary": "Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of imatinib therapy have an excellent long-term outcome, while patients without MCyR have a high progression risk. Since patients with primary cytogenetic resistance may benefit from more intensive therapy up-front, we sought to identify biomarkers to predict MCyR.  Keywords: Two group comparison to identify trasncriptomic signature that predicts response to therapy CD34+ cells were isolated from cryopreserved mononuclear cells of chronic phase CML patients with a complete cytogenetic response (CCyR) or >65% Ph-positive metaphases after 12 months of imatinib therapy (training set N=36). Gene expression profiles generated on amplified RNA using Affymetrix HG-U133 Plus 2.0 arrays were compared between responders and non-responders, using the criteria ANOVA p<0.1 and fold difference >I1.5I. A minimal response classifier derived from the comparison was used to predict response in a prospectively collected validation set using same criteria for responders/nonresponders (N=23).", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-14671", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-14671/samples/"}